Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Renaissance and GlaxoSmithKline Agree to a Transfer of Nine Products

By Pharmaceutical Processing | June 4, 2013

Renaissance Acquisition Holdings, LLC, a RoundTable Healthcare Partners portfolio company, and GlaxoSmithKline announced today that they have entered into an agreement giving Renaissance the rights in the USA to manufacture, market and sell six dermatology and three anti-viral products from GSK.

The products from GSK and Stiefel, a GSK company, which will be marketed through Renaissance’s branded division Prestium Pharma, include:

  • Evoclin® (clindamycin phosphate) Foam,1%
  • Extina® (ketoconazole) Foam,2%
  • Luxiq® (betamethasone valerate) Foam, 0.12%
  • Olux® (clobetasol propionate) Foam, 0.05%
  • Olux-E® (clobetasol propionate) Foam, 0.05%
  • Vusion® (miconazole nitrate 0.25%, zinc oxide 15% and white petrolatum 81.35%) Ointment
  • Zovirax® (acyclovir) Capsules
  • Zovirax® (acyclovir) Tablets
  • Zovirax® (acyclovir) Suspension

Pierre Fréchette, President and CEO of Renaissance, stated, “This transaction represents a significant milestone for Renaissance, and is in-line with our strategy of acquiring niche products that we can both manufacture within our internal network and market through our strong commercial group. The RoundTable team was instrumental in helping to source, diligence and complete such an important acquisition.”

Simon Jose, Stiefel President, said, “This agreement allows US patients to continue to have access to treatments they value and allows the Stiefel US Team to focus on growth and development of new treatments within our core dermatology portfolio.”

John Denman, General Manager of Prestium, commented, “We are excited to add these mature specialty brands to Prestium’s growing portfolio, and look forward to continuing to supply such important products to our customers and to patients across the country.”

 

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE